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Abstract.  The labeling patterns produced by radio- 
iodinated botulinum neurotoxin (t25I-BoNT) types A 
and B at the vertebrate neuromuscular junction were 
investigated using electron microscopic autoradiogra- 
phy.  The data obtained allow the following conclusions 
to be made.  (a)  ~2q-BoNT type A, applied in vivo or 
in vitro to mouse diaphragm or frog cutaneous pec- 
toris muscle,  interacts  saturably with the motor nerve 
terminal  only; silver grains occur on the plasma mem- 
brane,  within the synaptic bouton, and in the axo- 
plasm of the nerve trunk,  suggesting internalization 
and retrograde intra-axonal  transport of toxin or frag- 
ments thereof.  (b) t25I-BoNT type B, applied in vitro 
to the murine neuromuscular junction,  interacts like- 
wise with the motor nerve terminal except that a lower 
proportion of internalized  radioactivity is seen.  This 
result is reconcilable with the similar,  but not identi- 
cal, pharmacological action of these toxin types.  (c) 
The saturability of labeling in each case suggested 
the involvement of acceptors; on preventing the 
internalization  step with metabolic inhibitors,  their 
precise location became apparenL  They were found on 
all unmyelinated areas of the nerve terminal mem- 
brane,  including the preterminal 9xon and the synaptic 
bouton.  (d) Although  ~SI-BoNT type A  interacts  spe- 
cifically with developing terminal~  of newborn rats,  the 
unmyelinated plasma membrane Of the nerve trunk is 
not labeled, indicating  that the a¢ceptors are unique 
components restricted to the ner~  ~ terminal area.  (e) 
BoNT types A  and B have distinct acceptors on the 
terminal membrane.  (f) Having optimized the condi- 
tions for saturation of these binding  sites and cali- 
brated the autoradiographic proce4ture,  we found the 
densities of the acceptors for types A  and B to be 
~150 and 630/lxm  2 of membrane, respectively. It is 
proposed that these membrane acceptors target BoNT 
to the nerve terminal and mediat~ its delivery to an in- 
tracellular site, thus contributing to the toxin's  selec- 
tive inhibitory action on neurotransmitter  release. 
B 
OTULINUM toxins,  produced by the anaerobic bacte- 
rium Clostridium  botulinum in several antigenically 
different but structurally  related  forms,  are the most 
neurotoxic  agents known, and are responsible for the neu- 
roparalytic  condition, botulism (reviewed in reference 39). 
Although  many of these toxins  occur in  association with 
other protein(s)  that exhibit haemagglutinin  activity, the iso- 
lated neurotoxic protein has a molecular weight of ,,~150,000 
and  normally  consists  of two  heterologous  polypeptides 
(~100,000 and ,x,50,000). The unique toxicity  of both the 
free botulinum neurotoxin  (BoNT)  j (4, 37, 38, 42, 43) and 
its complex (5) is attributable  to their ability to inhibit irre- 
versibly the spontaneous and evoked release of acetylcholine 
at peripheral synapses.  The specificity of this action on the 
nerve terminal  is highlighted  by the absence of measurable 
effects on any other parameters  (6,  18). Therefore,  BoNT 
1.  Abbreviations  used  in  this  paper:  BoNT,  botulinum neurotoxin;  125I- 
BoNT, radioiodinated BoNT; LDso, amount of toxin that killed 50% of in- 
jected mice within 4  d. 
may prove useful for the identification  of functional  mem- 
brane components on motor nerves and in the elucidation of 
cellular processes concerned with transmitter  release. 
Light-microscopic  autoradiographic  studies  have  shown 
that ~25I-labeled BoNT type A binds Specifically (7, 22) and 
saturably (7) to components of the neuromuscular junction 
in mouse diaphragm.  The degree of  I  resolution at the level 
of the light microscope, however, did not permit precise lo- 
calization of the label in the synaptic region. Ultrastructural 
studies were necessary to distinguish ~etween pre- and post- 
synaptic labeling and to establish whether the neurotoxin was 
associated with the membrane and/0r intracellular  targets. 
Using  a  radioiodinated  derivative  of BoNT type A  (~25I- 
BoNT) that exhibits a high level of ne~rotoxicity (46), direct 
evidence for the saturable interaction ~af BoNT type A solely 
with the motor nerve terminal was pregented for the first time 
(8). When nerve-muscle preparation~ were treated with this 
neurotoxin  in vitro,  under conditions  known to block neu- 
rotransmission  (2), resulting  autoradiograms  showed a dis- 
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labeling was not restricted to the plasma membrane of the 
synaptic bouton, as silver grains were also present within the 
terminal cytoplasm. This finding was consistent with the sug- 
gestion (38) that the toxins neuroparalytic action involves a 
target site within the nerve terminal. 
It is important to note that the acceptors for the toxin were 
found (8) to be distributed uniformly on all areas of the syn- 
aptic bouton membrane; i.e., they were not restricted to the 
active zones where neurotransmitter release is thought to oc- 
cur (21). However, it is not known whether these membrane 
acceptors are unique to the terminal membrane or if they are 
also present on the myelinated axon. Furthermore, in rela- 
tion to the basis of BoNT-induced neuroparalysis, it is of in- 
terest  to  obtain  ultrastructural  evidence  for  the proposed 
transport of BoNT (15) along the nerve trunk. It needs to be 
established  whether BoNT  type A  and type B,  similar  in 
structure and overall pharmacological action (cf. references 
37, 39, and 4D, share common neuronal acceptors at the neu- 
romuscular junction. 
In this  study,  distinct  populations  of acceptors  for  ~25I- 
BoNT types A  and B were localized on all areas of the un- 
myelinated motor nerve terminal using electron microscopic 
autoradiography.  Moreover, the density of these acceptors 
was determined after conditions for their saturation had been 
established; their role in targeting BoNT to cholinergic nerve 
terminals and in mediating the subsequent internalization is 
discussed with respect to the molecular basis of botulism. 
Materials and Methods 
Radioiodination of Neurotoxins and Bovine 
Serum Albumin (BSA  ) 
BoNT types A and B were purified and radiolabeled by Dr. R. Williams 
of this  laboratory  (43,  46).  Radioiodination was carried out  using the 
chloramine-T method of Greenwood et al.  (13), with important modifica- 
tions.  The  125I-labeled preparations  were  of high  specific radioactivity 
(450-1,700  Ci/mmol) and retained 60-85%  of the neurotoxicity of native 
toxin preparations (representing 2  x  l0  s and 1.1  x  l0  s of the amount of 
toxin that killed 50% of injected mice in 4 d (LD~0)/mg for types A and B, 
respectively). BSA was radioiodinated in a similar manner; after accurate 
determination of its specific radioactivity, it was used as a standard for mea- 
suring the efficiency of the autoradiographic procedure. 
Tissue Labeling 
In vivo studies.  Mice were injected intraperitoneally with ~z~I-BoNT type 
A (1 pig, equivalent to 8.8  x  104 mouse LDs0 in 100 ~tl phosphate-buffered 
saline (PBS)/I% BSA; after death due to respiratory failure ("o2 hr after in- 
jection), the paralyzed diaphragm was excised, washed, and processed for 
electron microscopic autoradiography as detailed below. 
In vitro studies. Small pieces of mouse diaphragm tissue were incubated 
with ~25I-BoNT type A or B in 0.5 ml Krebs-Ringer's solution (124 mM 
NaCI,  5  mM KCI, 0.75 mM CaCI2,  10  mM glucose,  1.3  mM MgSO4, 
1.2 mM KH2PO4, and 20 mM Na2 HPO4, previously gassed for at least 30 
rain with 95% 02/5% CO2 and adjusted to pH 7.4) for 90 min at 22°C be- 
fore extensive washing in Krebs-Ringer's solution at 4°C (five times, 6 min 
each) and fixation with 2 % glutaraidehyde in the latter solution. After brief 
washing, the endplate regions were dissected, cut into small sections ('x,1 
x  0.5 nun), and treated with 1% OsO4 for 1 h, before being dehydrated in 
ethanol and embedded in Spurr's resin. Cutaneous pectoris muscle from a 
frog  was  processed  similarly  except  that  amphibian  Ringer's  solution 
(116 mM NaCI, 2 mM KCI, 2 mM CaCI2,  0.5 mM NaH2PO4,  3mM glu- 
cose, and5 mM Hepes [pH 7.2]) was used for the incubations and washes. 
Control samples were treated as above except that a 50-100-fold excess of 
native BoNT type A or B was included in the incubation medium. 
To examine the basis of toxin internalization, mouse diaphragm tissue 
was pretreated with 15 mM Na azide and labeling with ~I-BoNT types A 
and B was then examined. Concentration dependence of toxin binding was 
studied by incubating small pieces of the tissue with increasing concentra- 
tions of ~25I-BoNT (1.5-150 nM) for 90 min at 22°C, while the time course 
was investigated by labeling with type A radiolabeled toxin for various times 
(20-150 min), followed by the standard processing for microscopy. The dis- 
tribution of acceptors for ~25I-BoNT type A  along the motor nerve axon 
was investigated using the diaphragm of newborn rats, because the motor 
nerve is unmyelinat~l at this stage in development. The interaction of the 
different toxin types (A and B) at the motor nerve terminal was studied by 
pretreating the tissue with unlabeled toxin of one type for 1 h at 22°C fol- 
lowed by incubation with labeled toxin of the other type (for 90 rain). 
Electron-microscopic Autoradiography 
Autoradiograms were prepared essentially by the method of Salpeter and 
Bachmann (33). Ultrathin sections of pale gold interference color were cut 
using an ultramicrotome (LKB Instruments, Inc., Gaithersburg, MD) and 
transferred to formvar-coated slides with a platinum wire loop. At least six 
groups of three to five test sections from a minimum of two different blocks 
were placed along one side of the slide and at least three groups of two to 
three control sections were arranged on the other. This ensured that all sec- 
tions were exposed under the same conditions. The slides were then dipped 
in Ilford LA nuclear emulsion (10 g in 24 ml) at 32°C using a semiautomatic 
coating device; the speed of withdrawal was adjusted to give a monolayer 
of crystals with a purple interference color ("o170 nm thick). Slides were 
exposed for 3-6 wk at 4°C in light-tight plastic slide boxes. The emulsion 
was then developed in Kodak D-19 developer, fixed in 25% sodium thiosul- 
phate, and the formvar film was stripped off onto the surface of distilled wa- 
ter. Sections were picked up with parafiim and stained with 12% uranyl ace- 
tate for 20 min before being viewed in a Hitachi-600 electron microscope. 
Quantitation 
For comparison of the extent of labeling under different conditions, 25-35 
endplates from each preparation were photographed at a magnification of 
10,000 and prints were prepared at a  final magnification of 20,000.  The 
thickness of  the sections was measured by Small's method (40), using appro- 
priate folds in the sections; only those of similar thickness were used for 
quantitative studies. The membrane enclosing the synaptic boutons was 
traced onto acetate sheets and its length measured in micrometers using a 
digitizer (Hewlett-Packard Co., Palo Alto, CA). Grains were then counted 
and expressed per unit length of presynaptic membrane. 
Absolute Quantitation of  Acceptors for u~I-BoNT 
~pes A and B 
Acceptors were quantitated by the method of Fertuck and Saipeter (11). 
Nerve-muscle preparations were treated with saturating concentrations of 
type A or B  ~25I-BoNT for 90 min at 22°C to ensure total  occupancy of 
specific sites at the motor nerve terminal. After small samples of the end- 
plate regions were processed for microscopy, at least nine groups of three 
to five pale gold tissue sections from different blocks containing large num- 
bers of nerve endings were arranged on each slide. After exposure periods 
ranging from 1 to 6 wk, the emulsion was developed and the stained sections 
viewed in the electron microscope. Nerve terminals from sections of similar 
thickness only were photographed and prints prepared at a magnification of 
28,300.  The density of acceptors was determined using the following equa- 
tion (11): 
G×D  A 
sites/ktm2  =  124,800  (1  -  e -°.°t155') ×S~' 
where G is the grain density (No. grains/I.tm 2 membrane), D is the decays 
required for one developed grain (or l/percent efficiency), t is the exposure 
time in days, A is Avogadro's  number (6.023  ×  102o molecules/mmol), So 
is the specific activity of the radiolabeled toxin at the beginning of the ex- 
posure period (curies per miilimole), and C is the disintegrations per minute 
or 2.22  ×  1012. Grain density was determined by measuring the length of 
the presynaptic membrane in micrometers by digitization and counting the 
silver grains along its length. The percent efficiency of the autoradiographic 
technique  used  was  determined by  processing  sections of  1251-BSA of 
known radioactivity for electron microscopic autoradiography and develop- 
ing the emulsion after different exposure periods (34). The number of grains 
produced per radioactive decay could then be calculated. 
The Journal  of Cell Biology, Volume 103, 1986  522 Figure 1. Interaction of ~25I-BoNT  type A with motor nerves  after in vivo administration  to mice.  (a) Motor nerve terminals  (nO labeled 
with J25I-BoNT  type A after intraperitoneal  injection  of ',~1 lag of radioiodinated  toxin (in 100 ~tl PBS/I%  BSA) into a mouse. Autoradio- 
grams were developed after 3-wk exposure.  Note the absence of silver grains on muscle fibers (mf), Schwann cells (S),  blood vessels 
(bv), and collagen (c).  (b) Transverse  section through a myelinated  axon from a mouse diaphragm treated  as above.  Grains are seen  in 
the axoplasm (a) but no labeling  of the protective  myelin sheath  (m) is observed. 
Results 
Labeling Profiles for ~I-BoNT I~pes A  and B in 
Mouse Diaphragra and Frog Cutaneous Pectoris Muscle 
Sections of mouse diaphragm tissue labeled with  ~25I-BoNT 
type A in vivo showed deposition of silver grains at the motor 
nerve  terminal  (Fig.  1  a).  No  labeling  of muscle  fibers, 
Schwann cells, blood vessels, collagen fibrils, or myelin was 
detected in any of the sections,  emphasizing the specificity 
of the interaction of radiolabeled BoNT type A with the mo- 
tor nerve terminal.  At the  labeled  nerve terminals,  grains 
were  observed  both  on the presynaptic plasma  membrane 
and within the cytoplasm, indicating the involvement of an 
internalization step (Fig.  1 a).  Most of the developed grains 
(63 % of the total) were on the membrane (Table I) and could 
be seen on all areas of the unmyelinated nerve terminal (see 
below).  Moreover,  silver  grains  were  observed  within  the 
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Terminals Labeled under Different Conditions with 
125I-BoNT Types A and B 
Distribution  of 
grains with 
respect to the 
plasma membrane 
% of total 
Na Azide 
Labeling conditions  (15 mM)  On  Inside 
In vivo 
~25I-BoNT type A(~I  I.tg)  -  63  37 
In vitro 
125I-BoNT type A(15  nM)  -  62  38 
125I-BoNT type A(11  nM)  +  100  - 
125I-BoNT type B(10  nM)  -  75  25 
125I-BoNT type B(20 nM)  +  100  - 
Large numbers (20-50)  of nerve endings from mouse diaphragm preparations 
treated with t25I-BoNT in vivo (after intraperitoneai injection of the mouse) or 
in vitro (in Krebs-Ringer's solution for 90 min at 22°C), using the conditions 
specified,  were processed  for electron  microscopic  autorediography  (as de- 
tailed in Materials and Methods) and photographed.  When Na azide was in- 
eluded  (+),  the  samples  were preincubated  for 30  min before  addition  of 
BoNT. The silver grains on the nerve membrane and inside the synaptic bouton 
were counted independently and expressed as percent of the total. A grain was 
considered to be on the membrane if it was located within 60-70 nm of the 
plasma membrane. 
axoplasm of myelinated axons,  suggesting  that retrograde 
intra-axonal transport had occurred (Fig.  1 b). 
A similar pattern of  labeling was observed in sections from 
samples treated with 15 nM 125I-BoNT  type A in vitro, thus 
confirming the validity of the in vitro model for localization 
studies (Fig. 2 a).  Silver grains were observed only at the 
unmyelinated motor nerve terminals; these occurred both on 
the plasma membrane (62 %) and within the terminal (38 %) 
(Table  I).  The  internalized  radioactivity  did  not  appear 
confined to any particular intraterminal compartment, al- 
though  grains  were  sometimes  seen  associated  with  the 
membrane of vacuolar structures. Control sections, treated 
with 125I-BoNT  type A in the presence of excess native neu- 
rotoxin, were virtually devoid of silver grains (Fig. 2 b); na- 
tive BoNT reduced the extent of labeling to 4 % of that seen 
in test samples. Collectively, these results showed that the in- 
teraction of 125I-labeled type A  toxin with its target tissue 
was both selective and saturable, thus demonstrating the in- 
volvement of acceptors. Saturable labeling of the neuromus- 
cular junction was also observed using light-microscopic au- 
toradiography after incubation of the tissue  with 0.2  nM 
~2SI-BoNT type A, a concentration in the range of that re- 
quired for neuroparalysis in vitro (38), but too low to allow 
detection in ultrathin sections. Where autoradiography was 
combined with histochemical localization of acetylcholines- 
terase (7, 44) (to label the neuromuscular junction), silver 
grain clusters coincided with areas reacting with acetylthio- 
choline (data not shown). 
~25I-BoNT type B also interacted specifically and satura- 
bly with the motor nerve terminal (Fig. 2, c and d). After 
ll-d exposure,  grains  were deposited both on the plasma 
membrane and within the synaptic bouton itself, suggesting 
that uptake of toxin had taken place, as previously observed 
with type A, except that the extent of internalization was con- 
siderably  less  (Table I).  As  found with  A,  intraterminal 
grains  were  often associated  with  vacuole-like structures 
(Fig. 2 c); likewise, the presence of silver grains within my- 
elinated axons suggested retrograde axonal transport of ra- 
dioactivity had taken place (data not shown). 
A similar pattern of labeling was also observed with frog 
cutaneous pectoris (Fig. 3); silver grains were observed both 
on the membrane and in the cytoplasm of test sections la- 
beled with  t25I-BoNT type A,  while  controls were com- 
pletely devoid of silver grains, indicating saturability of the 
binding (data not shown). The extent of labeling at the am- 
phibian nerve terminal was, however, considerably less than 
in mammalian tissue; this difference is reconcilable with the 
apparent lower sensitivity of frog muscle to the action of the 
toxin (31). 
Interaction olives A and B Botulinum Neurotoxins 
Preincubation of a mouse nerve-hemidiaphragm with a 100- 
fold excess of type B neurotoxin did not prevent binding or 
internalization of mI-BoNT type A at the motor nerve ter- 
minal (Fig. 4 a). Quantitative analysis of resultant autoradio- 
grams (see Materials and Methods) showed that the number 
of grains per micrometer of  plasma membrane was the same 
in sections incubated with mI-BoNT type A in the presence 
and absence of unlabeled type B (Table II). 
In the converse experiment, type A did not prevent com- 
pletely the binding  of t25I-BoNT type B,  as  silver grains 
were still seen at terminals preincubated with unlabeled type 
A neurotoxin (Fig. 4 b).  However, quantitation of the data 
obtained demonstrated that specimens exposed to 125I-BoNT 
type B  in  the presence of type A  showed a  24%  reduc- 
tion in the extent of labeling relative to those treated with 
radioiodinated type B alone (Table II). Thus, in contrast to 
the lack of antagonism seen when terminals were labeled 
with mI-BoNT type A in the presence of type B BoNT, this 
partial  inhibition suggests that type A  interacts indirectly 
with at least some of the acceptors for type B. 
Localization  of  Acceptors for mI-BoNT 1)~es A and B 
at the Murine Motor Nerve Terminal 
Although the saturability of the labeling of motor nerve ter- 
minals with mI-BoNT in vitro implicated membrane accep- 
tors, their exact location was not apparent due to masking by 
grains resulting from internaliTed radioactivity. As detailed 
in the accompanying report (2), the internalization step can 
be prevented totally using inhibitors of energy production 
(such as Na azide and dinitrophenol) and by low temperature 
(e.g., 4°C);  this allows the interaction of the radiolabeled 
toxins with their acceptors to be examined. 
In the presence of 15 mM Na azide, radioactivity seemed 
to occur solely on the plasma membrane (Fig. 5, a  and b; 
Table I); nonspecific labeling was minimal (data not shown). 
To ensure that the nerve terminal membrane was indeed the 
source of the silver grains (particularly those opposite the 
postsynaptic folds [29]),  quantitative studies were carried 
out as follows (35): the distance from the midpoint of at least 
500 silver grains to the plasma membrane was measured and 
used to construct a grain-density distribution histogram. As 
Fig. 6 a  shows, the distribution was bell-shaped, indicating 
that the majority of grains were found on the terminal mem- 
brane or very close to it. Since the scatter is symmetrical on 
both sides of the "biological line source," the presence of ac- 
ceptors on the postsynaptic plasma membrane can be ex- 
The Journal of Cell Biology, Volume 103, 1986  524 Figure 2. Interaction of 125I-BoNT types A and B with the murine motor nerve terminal in vitro detected by electron microscopic autoradi- 
ography. (a) Motor endplate from a mouse diaphragm treated with t25I-BoNT type A  (15 nM).  Sections were exposed for 3 wk.  Silver 
grains are seen on the nerve terminal membrane (arrows) and in the cytoplasm (arrowheads). (b) Control preparation treated as described 
in a  in the presence of a  100-fold excess of unlabeled BoNT type A. (c) Five synaptic boutons from a nerve-muscle preparation treated 
with ~25I-BoNT  type B (10 nM) and exposed for 11 d. Note the presence of silver grains on the presynaptic plasma membrane and within 
the cytoplasm where they are often associated with the membrane of vesicular structures (arrows). (d) Control nerve terminals treated 
with ~25I-BoNT type B in the presence of excess (100-fold) unlabeled toxin showed ,o1%  of the labeling seen in test sections indicating 
that, as in a, the interaction is saturable. See Fig.  1 legend for explanation of symbols. 
cluded.  The  half-distance value,  i.e.,  the  distance from  a 
radioactive line within which half of  the developed grains are 
located, was determined from the integrated grain distribu- 
tion histogram shown in Fig. 6 b, and found to be ,o56 nm. 
At a distance of only 100 rim, the number of grains was very 
low, indicating that the autoradiographic method used gives 
good resolution. 
The saturable acceptors for both toxin types were not re- 
stricted to the active zones but extended uniformly to all the 
unmyelinated terminal arborizations of the nerve as far as the 
Black and Dolly Botulinum  Neurotoxin Acceptors on Motor Nerves  525 Figure 3. Binding and internalization of uSI-BoNT type A at the 
amphibian neuromuscular junction.  Cross section of a nerve ter- 
minal from frog cutaneous pectoris tissue incubated with  15 nM 
125I-BoNT type A in amphibian Ringer's solution. The pattern of 
labeling is similar to that at the mammalian nerve terminal; silver 
grains are observed on the presynaptic membrane and within the 
cytoplasm. 
terminal node of Ranvier (Fig. 7, a-c). No grains were de- 
tectable on the protective myelin sheath, but the possibility 
of specific acceptors also occurring on the plasma membrane 
of  the myelinated axons (to which toxin molecules had no ac- 
cess) could not be excluded. As the motor neurons innervat- 
ing the diaphragm of newborn rats are still unmyelinated at 
this stage of development (47) and the Schwann cells that 
loosely surround the axons do not appear to prevent toxin 
molecules from reaching the axonal plasma membrane, the 
possible distribution of  acceptors on the axon could be evalu- 
ated in this preparation. Newborn rats are highly susceptible 
to  intoxication by  uSI-BoNT type A,  dying within  a  few 
hours of an intraperitoneal injection of low (<1  LDs0 for 
adult mice) doses of the toxin. Accordingly, saturable bind- 
ing of t~5I-BoNT type A was detected at the developing mo- 
tor nerve terminals in test sections (Fig. 8, a and b); control 
autoradiograms were completely devoid of  silver grains (Fig. 
8 c). Although a few grains were present on the axonal areas 
nearest the developing terminal matrices, no labeling was ap- 
parent in the large bundles of unmyelinated axons more dis- 
taut from the terminal regions (Fig. 8 d). These observations 
suggest that the acceptors are located only in those areas of 
the axonal plasma membrane not destined to become myeli- 
nated, i.e., the terminal areas. Most of the nerve terminals 
observed were too small to allow detection of internalization, 
but in those that were slightly larger uptake was apparent 
(Fig.  8 b). 
Density of  Acceptors for L~I-BoNT 1~es A  and B on 
the Unmyelinated Nerve Terminal Membrane 
Optimization of  conditions for saturation of  specific accep- 
tors with u~I-BoNT. Inhibition of the internalization step of 
intoxication by  t25I-BoNT types A  and B  using  metabolic 
inhibitors permitted the absolute quantitation of their accep- 
tors at the nerve terminal. To carry out such determinations, 
it was essential to establish the toxin concentration and incu- 
bation period required to saturate the sites for each toxin 
type. Saturation of the acceptors in the presence of azide was 
achieved using 15 nM t25I-BoNT type A for 90 min at 22°C 
(Table l~I).  A  significant amount of radioactivity was seen 
associated with motor nerve terminals  after only 20 min 
(84% of maximum binding, see Table HI); maximum bind- 
ing was attained by 90 min with this toxin concentration, de- 
spite the restricted diffusion into this tissue (1). 
In the case of ~I-BoNT type B (Table m), the labeling 
observed using 20- and 100-riM concentration (for 90 min at 
22°C)  did not differ appreciably;  for quantitative studies, 
100 nM was used to ensure saturation. 
Calibration of  the autoradiographic technique.  To deter- 
mine the percent efficiency  (32) of  the method used routinely, 
ultrathin sections containing a known amount of radioactiv- 
ity (in the form of uSI-labeled  BSA) were processed for au- 
toradiography and developed after varying lengths of time. 
A linear increase was observed (Fig. 9 a) in the number of 
silver grains produced during the first 3-wk exposure; longer 
exposure times, however, resulted in a slight leveling of the 
curve. Percent efficiency (Fig. 9 b) decreased from •63  % 
(almost maximum;  see reference 32)  for the  shortest ex- 
posure time (4 d) to 57% for the longest (42 d), the average 
being 60  +  3.2%  (n  =  6). The background grain density, 
obtained by photographing random areas of the sections that 
did not contain 125I-labeled BSA, was negligible. 
To ensure that 60 % efficiency was applicable to test speci- 
mens  incubated with  uSI-BoNT,  groups  of sections  from 
samples that had been previously saturated with ~z~I-BoNT 
type A and processed for electron microscopic autoradiogra- 
phy were developed each week for 6  wk.  The number of 
grains per micrometer of plasma membrane was then deter- 
mined for each exposure time and expressed as a function 
of time (Fig.  10). The plots obtained for L25I-BSA and ~sI- 
BoNT type A were very similar and 60% was considered a 
valid estimate of the efficiency in this system. 
Acceptor densities.  The average number of acceptors for 
BoNT type A  was  152(+  20%)/lxm  2 of membrane when 
150 nM  ~25I-BoNT and 7-42-d exposure were used (Table 
Table II. Interaction of Types A andB BoNTat 
Motor Nerve Terminals 
Number of grains per micrometer 
Incubation conditions  plasma membrane 
12SI-BoNT  type A  (15  nM) 
Type B  BoNT (1.5  ltM)  + 
~25I-BoNT  type A  (15  nM) 
125I-BoNT  type B  (10 nM) 
Type A  BoNT (1  IXM) + 
t25I-BoNT type B  (10  nM) 
0.67  (100%) 
0.71 (106%) 
1.10 (100%) 
0.84  (76%) 
Samples of mouse diaphragm tissue were preincubated in Krebs-Ringer's solu- 
tion with unlabeled toxin of one type (A or B) for 1 h at 22°C before the addi- 
tion of radioiodinated  toxin of the other. Incubation was carried out for 90 min 
(at 22°C), followed by washing and routine processing for autoradiography. 
After 3-wk exposure, the sections were viewed in the electron microscope and 
"~20-30 endplates from each preparation were photographed. The total length 
of presynaptic membrane seen in the prints was measured by digitization; the 
number of grains associated with the nerve terminals was determined and grain 
density was calculated for each preparation. This allowed the labeling observed 
under different conditions to be compared quantitatively. 
The Journal of Cell Biology,  Volume  103, 1986  526 Figure 4.  Interaction of types A and B BoNT at the murine motor nerve terminal. (a) Cross-sectional view of four synaptic boutons labeled 
with t2~I-BoNT type A in the presence of unlabeled type B BoNT. The tissue was preincubated with type B BoNT (1.5 ~tM) for 1 h at 
22°C before incubation for 90 rain with radiolabeled type A, at a final concentration of 15 nM. (b) Section of a motor endplate pretreated 
with unlabeled type A BoNT (1  IxM) for 1 h at 22°C followed by addition of 125I-BoNT type B to a final concentration of 10 nM, with 
further incubation for 90 min. Silver grains are present at the nerve terminals, but labeling is somewhat less extensive than that observed 
in control specimens. 
Black and Dolly  Botulinum Neurotoxin Acceptors on Motor Nerves  527 Figure 5.  Localization of acceptors for u~I-BoNT  types A and B at the murine motor nerve terminal. Nerve-muscle  preparations were 
treated with Na azide (15 mM) for 30 min at 22°C before a 90-rain incubation with ~25I-BoNT  type A or B, in the presence of the meta- 
bolic inhibitor. Autoradiograms of samples treated (a) with ~5I-BoNT  type A (150 nM) or (b) with type B (20 nM). 
IV). When quantitation of acceptors was performed using 15 
and  35  nM  ~25I-BoNT type A,  similar  numbers  were ob- 
tained, confirming that these concentrations do, in fact, satu- 
rate the binding sites (Table III). The density of 125I-BoNT 
type B  sites was  determined, likewise,  by processing two 
different blocks of diaphragm tissue (treated with  100 nM 
~25I-BoNT type B, see above) for electron microscopic auto- 
radiography. Using an efficiency value of 62 % (more appro- 
priate for the exposure used),  the average site density was 
627  +  21% (the range of values being 495-759; Table IV). 
Hence, the density of sites for ~25I-BoNT  type B is approxi- 
mately four times greater than that for A. 
Discussion 
The  grain  distribution  in  autoradiograms  of mouse  dia- 
phragm labeled in vivo with ~25I-BoNT  type A using a con- 
centration (extrapolated) of <3  nM  was  indistinguishable 
from that seen after in vitro labeling with 1.5 nM (or higher); 
this emphasizes the validity of the latter as a means for ob- 
serving labeling patterns that are relevant to BoNT poison- 
ing. Moreover, the presence of silver grains in the axoplasm 
of  myelinated nerves demonstrates that the toxin, or a portion 
of the molecule, undergoes retrograde intra-axonal transport 
as has been shown for tetanus toxin (30) and nerve growth 
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Figure 6. Histogram of experimental grain- 
density  distribution  around  a  radioactive 
line source:  determination  of the half-dis- 
tance  (HD)  value  (35).  (A) The distance 
from a biological line source (i.e., the plas- 
ma  membrane of motor nerve terminals 
treated with t2~I-BoNT  type A in the pres- 
ence of Na azide as described in Fig. 5) to 
the midpoint of >500 silver grains was mea- 
sured and a histogram of grain-density dis- 
tribution  about  the  line  was  constructed 
with the data.  Because this histogram ap- 
peared  symmetrical  on  both  sides  (indi- 
cating that the source was in fact a line), a 
one-sided histogram (shaded bins) was also 
plotted. A smooth curve was then drawn in 
by eye. Most of the grains were located on 
or very close to the membrane, as reflected 
by the bell-shaped curve. (B) Following +.he 
method of Salpeter et al.  (35), the results 
shown in A were used to plot an integrated 
grain distribution histogram.  Each column 
gives the total number of grains within that 
distance  from the  source.  The number of 
grains  changed very little after ,~300  mn 
and counting was stopped at a cut-off dis- 
tance of ,~600 ran. The half-distance value 
was  determined  readily  from  this  histo- 
gram: the total number of grains is 532; half 
the total (i.e., 266 grains) can thus be found 
within •56  um of the source. 
factor (19).  The pathway for retrograde axonal transport of 
exogenous proteins usually begins with uptake by endocyto- 
sis  at  the  nerve  ending  or  unmyelinated  portions  of the 
preterminal axon (12). Protein is carried in the axon inside 
various vesicular or tubular organelles to the cell body where 
it may be transferred to lysosomes (25), to some other com- 
partment  in  the  cell,  or  by  transsynaptic  migration  to 
presynaptic terminals that synapse on that cell body (e.g., 
tetanus toxin).  The purpose for the neural ascent of BoNT 
is unknown; however, studies carried out by Hagenah et al. 
(16),  in  which  toxin  injected  into  muscle  and  allowed  to 
ascend  the  motor  nerve  was  found  not  to  affect  central 
cholinergic  neurotransmission  suggest that,  unlike  tetanus 
toxin,  a  (modified) inactive form is involved. Transport of 
BoNT to the cell body may be necessary for its degradation 
because the neuronal cell body is richer in both primary and 
secondary lysosomes than the axon and nerve endings (24). 
The pattern of labeling with type B is comparable to that 
seen with A, in accordance with the related pharmacological 
action  of these  toxin  types.  However,  although  both  neu- 
rotoxins appear to be internalized, the extent of uptake of B 
is appreciably lower (~40% less) than that of type A. If, as 
has been suggested previously (38),  internalization of toxin 
is required  for expression of toxicity, the demonstrable re- 
duction in the proportion of translocated radioactivity could 
account for the lower toxicity of BoNT type B  in mice. 
Using the inhibitor of oxidative phosphorylation Na azide 
to prevent internalization of radioactivity, the exact location 
of the specific acceptors for t25I-BoNT types A  and B was 
established. Resolution studies confirm that these are indeed 
presynaptic and membrane-associated; this result is consis- 
tent with the lack of direct postsynaptic effects being induced 
by BoNT (36).  In both cases, silver grains were uniformly 
distributed on all unmyelinated areas of the nerve terminal 
membrane; thus, the acceptors are not located solely in the 
synaptic region but also on preterminal axonal plasma mem- 
brane. Since the protective myelin sheath does not allow ac- 
cess of molecules to the axonal membrane it encloses, the 
presence of acceptors in areas beyond the terminal node of 
Ranvier was  investigated in  newborn rats.  Myelination of 
motor neurons is incomplete at this  stage of development 
(26),  leaving the entire length of the nerve trunk exposed 
to  the  external  environment.  Saturable  acceptors  for  12sI- 
BoNT type A were found only on the terminal membrane of 
these immature synapses; large bundles of nerves destined 
to become myelinated were unlabeled. It appears, therefore, 
that the sites are restricted to the unmyelinated terminal ar- 
borizations of the motor nerve; a similar distribution was re- 
cently reported for ct-latrotoxin binding sites except that only 
the  synaptic  bouton  membrane,  and  not  the  preterminal 
axon, was labeled (45).  It is interesting that types A and B 
BoNT do not appear to share common membrane acceptors 
at the nerve terminal. Further evidence for the presence of 
a distinct population of sites for each toxin type is given by 
their different densities. The absolute number of sites for the 
two toxin types represents the first direct measurement of the 
density of any component on the unmyelinated mammalian 
motor nerve terminal membrane. The number of sites per 
Black and Dolly Botulinum Neurotoxin Acceptors on Motor Nerves  529 Figure 7. Saturable acceptors for ~2SI-BoNT  on the membrane of unmyelinated axons. (a) Autoradiogram of a longitudinal section through 
an unmyelinated axon and a synaptic bouton labeled with ~:5I-BoNT  type A in the presence of Na azide (15 mM). Silver grains are seen 
on the plasma membrane of the terminal axon (arrows). S, Schwann cell processes loosely surrounding the axon. Arrowheads, the area 
of the active zones, from which transmitter  release is thought to occur. (b) Transverse section through an unmyelinated axon (a) which 
is surrounded loosely by Schwarm cell processes (S). The tissue was treated with ~25I-BoNT  type A (15 nM).  Silver grains are seen as- 
sociated with the axonal plasma membrane and also with intra-axonal vesicles (arrows). (c) Unmyelinated axon labeled with tzSI-BoNT 
type B (10 riM) right up to the terminal node of Ranvier (arrow). Note that in this preparation, which was treated in the absence of metabolic 
inhibitors,  all silver grains are associated with the neuronal plasma membrane. 
square micrometer of membrane for uSI-BoNT types A and 
B  is  153  5:31  and 627  +  131, respectively. 
The acceptors studied autoradiographically appear to be 
involved in the action of the toxin because of the discrete and 
selective labeling patterns seen both in vivo and in vitro with 
BoNT concentrations in the range that blocks neurotransmis- 
sion (38). Additional support for this deduction is provided 
by their demonstrated presence only at terminals (3) where 
BoNT effectively inhibits transmitter release (3, 8). Regard- 
ing the precise manner in which the acceptors participate in 
the  neuroparalytic action of the neurotoxin,  analogies are 
apparent  with  other  bacterial  and  plant  toxins  in  certain 
respects. As in the case of these other toxins (e.g., diphtheria 
toxin, tetanus toxin, abrin, ricin, and modeccin), BoNT ac- 
ceptors may ensure that toxin is concentrated on the cell sur- 
face (for review, see reference 28) and directed to a particular 
intraceUular  vesicular  compartment.  In  the  light  of  the 
results presented here the theoretical "pipe and valve" model 
of Hanig and Lamanna (17), which suggests that the interac- 
tion of BoNT with surface acceptors is directly responsible 
for toxicity, does not seem a viable proposition. The accep- 
tors for L25I-BoNT types A  and B, which appear to be dis- 
tinct, are not restricted solely to the active zone areas oppo- 
site the postsynaptic folds (although the presence of a small 
number of  higher affinity sites within the active zones has not 
been excluded).  Furthermore, the calculated density of ac- 
ceptors far exceeds the estimated number of 500 active zones 
per nerve terminal (20).  Finally,  it is difficult to reconcile 
The Journal of Cell Biology, Volume 103, 1986  530 lqgure 8.  Interaction of ~25I-BoNT  type A with the developing  motor nerves  of newborn rats.  The diaphragm of a newborn rat was in- 
cubated with ~2~I-BoNT  (30 nM) in 0.5 ml Krebs-Ringer's  solution for 90 min at 22°C, followed by extensive  washing  at 4°C. Sections 
processed for autoradiography were exposed for 4 wk. (a) Developing motor nerve terminals  labeled with I~I-BoNT. Note the postsynap- 
tic folds (pf) in the muscle cell and the numerous small axon terminals  (t) embedded in an overlying Schwann cell (S). (b) Larger nerve 
terminal  from a newborn rat diaphragm labeled  with 125I-BoNT  type A. Note the internalized  silver grain (arrow) possibly associated  with 
a vesicular structure (v), the overlying Schwann cell  (S), and the postsynaptic  folds in the muscle cell  (pf).  (c) Control nerve terminal 
(t) treated  with radiolabeled  BoNT in the presence of excess  (3 I.tM) unlabeled  toxin.  (d) Unmyelinated  axons (a) loosely wrapped by 
Schwann cells (S) in a newborn rat diaphragm preparation treated as described above. Although the nerve terminal  (t) areas (left) are labeled 
with 125I-BoNT, no silver  grains are detectable  on the unmyelinated  axonal  membrane. 
this theoretical proposal with the apparent requirement  for 
toxin  internalization  before expression  of neurotoxicity  (5, 
38)  and  with  the  action of other  toxins  of similar  overall 
structure.  It does not appear,  therefore,  that BoNT acts by 
blocking  physically  the  neurotransmitter  release  sites;  of 
course, the possibility that toxin molecules interact with the 
active  zones  intracellularly  remains  likely.  Another  pro- 
posed model suggests that the toxin acts as a  Ca ++ channel 
blocker (23). The distribution of BoNT sites, however, does 
not correspond with that predicted for Ca ++ channels from 
electron microscopic freeze-fracture studies (21).  Moreover, 
the  absence  of binding  sites  for BoNT  at  adrenergic  and 
several other synapse types (3,  8) would exclude the Ca ++ 
channel as its possible acceptor, as this channel ought to be 
similar  in,  at least,  some of the nerves  studied.  In accord 
with  this,  BoNT is  known to be  ineffective towards  Ca ++ 
currents measurable  in presynaptic membranes  (9,  14). 
Regardless of the physiological function of the acceptors, 
their density is far too high to be reconcilable with the num- 
ber of neurotoxin molecules  needed to induce paralysis  in 
vivo. For example, the LDs0 for a mouse is ~1.2  x  10  -I1 g 
or 8  x  10  -17 mol, equivalent to 5  x  107 molecules of BoNT 
type A.  From this  LDs0,  it can be calculated that an abso- 
lute maximum of llY-llY molecules are required  to induce 
blockade of  neurotransmission at each synapse (calculated as 
described in reference 39). As the observed densities of ac- 
ceptors are ~150 and 630/gm  2 of membrane for t2SI-BoNT 
types A and B, respectively, these greatly exceed the number 
of molecules needed to inhibit neurotransmitter release at a 
synapse. Thus, these autoradiographic data appear to dismiss 
totally a "one-hit" model for the mechanism of  action of  these 
BoNT types.  This is  further supported by the finding that, 
although types A  and B have a  similar pharmacological ac- 
tion at the neuromuscular junction,  they do not appear to 
share acceptors on the neuronal membrane. 
Collectively,  our  findings  show  that  the  acceptors  are 
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Time Course of the Binding of Types A and B ~zSI-BoNT 
to Nerve Terminal Membranes 
Number of grains per micrometer 
of plasma membranes 
Toxin concentration 
(90 min)*  Type A  Type B 
nM 
1.5 
10.0 
15.0 
20.0 
35.0 
100.0 
Incubation  with 15 
nM toxin* 
0.23  -t- 0.03 
-  0.53  +  0.06 
0.55  +  0.06 
-  0.81  -t- 0.07 
0.56  -t- 0.06 
-  0.95  +  0.07 
min 
20  0.46  +  0.08 
90  0.55  +  0.06 
150  0.53  +  0.09 
* Mouse diaphragms were preincubated in Krebs-Ringer's solution containing 
15  mM  Na azide  for 30 min at 22°C  followed by labeling  with  ~25I-BoNT 
type A or B in the latter solution,  under the conditions specified above. 
After  the  standard  processing  for electron  microscopic  autoradiography, 
average grain densities were determined at a minimum of 25 endplates from 
several sections (of the same thickness) taken from different blocks of the tis- 
sue; these (+ SE) are expressed (27) per unit length of presynaptic membrane. 
responsible for  targeting  BoNT  to  motor  nerve  terminals 
where they mediate (2) internalization; this could facilitate 
inhibition of acetylcholine release by direct or indirect inter- 
action of the toxin (or a fragment) with an intraterminal com- 
ponent  concerned  with the  process.  The  large number  of 
acceptors detectable, relative to the number of BoNT mole- 
cules  required  to  cause  neuroparalysis,  should  ensure  an 
efficient delivery of toxin to its pharmacological target; this 
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Figure 10. Time course of grain development on the nerve terminal 
membrane  labeled with  t25I-BoNT. Sections of nerve  terminals 
previously labeled with 150 nM uSI-BoNT type A (in the presence 
of Na azide), were developed each week for 6 wk. 20-34 endplates 
(100-300  silver grains) were photographed for each time point. 
Grains were counted and the length of  the nerve terminal membrane 
was determined by digitization. Grain density (number of grains per 
micrometer membrane) was then plotted as a function of exposure 
time; for quantitative analysis exposure times of 7-28 d are optimal. 
could be one contributory factor to its unique potency. Apart 
from  being  utilized  by  BoNT,  these  naturally  occurring 
membrane components undoubtedly must serve some as yet 
unidentified  function  in  their  own  right.  Apparently,  the 
BoNT  types recognize determinants unique to cholinergic 
(3) nerve terminals, implicating them in some characteristic 
function. The toxins may thus prove to be powerful tools for 
investigations on the nature of these terminals; they may also 
provide insight into the differences between the unmyelinated 
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Figure 9.  Grain density as a function of expo- 
sure time and efficiency of  the autoradiographic 
procedure.  Ultrathin  sections  of  embedded 
~25I-BSA, containing a  known amount  of ra- 
dioactivity, were processed for electron micro- 
scopic autoradiography and developed in Ko- 
dak D-19 after various exposure times (4--42 d). 
(A) The average number of silver grains pro- 
duced by this fixed amount of labeled material 
during  different  exposure  periods  expressed 
graphically as a function of  time. Note that dur- 
ing the first 3 wk of exposure, the increase in 
the number of grains produced was linear; the 
curve only levels off significantly  after 30-d ex- 
posure time. (B) Percent efficiency values were 
obtained from the total number of disintegra- 
tions occurring per unit volume of labeled ma- 
terial during a specified exposure time, given 
by the  following equation  (10): D  =  Do  × 
124,000  [1  -  e-°°u55(o], where D  is the total 
disintegrations per unit volume during time t, 
Do is the disintegrations per unit volume at the 
start of exposure, t is the exposure time in days, 
and the number of grains produced as a result 
of these decays, as shown here: % efficiency  = 
(No. of grains  x  100)/(No.  of decays). 
The Journal of Cell Biology, Volume 103, 1986  532 Table IV. Densities of Acceptors for lesI-BoNT 
Types A and B at Murine Nerve Terminals 
Concentration  Exposure  Grain  Sites/ttm ~ plasma 
of ~25I-BoNT  time  density  membrane 
nM  d  per #m  2 
Type A 
150  7  4.2  157  +  33 
14  8.3  161  +  33 
21  11.3  153  +  31 
28  14.5  153  +  30 
35  17.5  153  +  30 
42  18.5  141  +  28 
average  153  +  30 
35  28  7.5*  150  +  31 
15  28  7.3*  146  +  30 
Type B 
100  11  13.4  623  +  129 
100  11  13.5  631  _  132 
Using the grain-density  values obtained for each time point, the experimental 
value for efficiency (60 and 62% for BoNT A and B, respectively) and the spe- 
cific radioactivity of BoNT A and B (630 and 1,241 Ci/mmol, respectively), the 
number of acceptors for each type was calculated as detailed in Materials and 
Methods.  Error in these calculations was determined by an adaptation of the 
method of Matthews-Bellinger  and Salpeter (27). 
* The specific radioactivity  for the preparation  used was 657 Ci/mmol. 
nerve terminal membrane and the myelinated axonal mem- 
brane of motor neurons. 
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